BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Sun Pharmaceutical Industries Ltd. reported robust revenue growth of 14% YoY in Q2 FY23 aided by-
global ramp-up of specialty products,
focus on domestic market and
steady growth in rest of world market.
Sun Pharma's significant investments and efforts in specialty business started paying off in upward trajectory with 28% YoY growth in H1 FY23.
Sustained momentum in specialty will help in improving operating leverage and margins too. Domestic formulations (32% of total revenue) continue to outperform Indian pharma market.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
